F. Brun

发表

Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial

A. Torbicki, H. Ghofrani, G. Simonneau, 2012 .

The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection

P. Póvoa, F. Bolgert, N. Weiss, 2019, Intensive Care Medicine.

Sustained effect of macitentan, a novel oral endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension

G. Simonneau, L. Rubin, H. Ghofrani, 2013 .

Reduction Of Pulmonary Arterial Hypertension (Pah)-Related Hospitalizations With Macitentan In The Randomized Controlled Trial Seraphin

A. Torbicki, O. Sitbon, L. Rubin, 2013 .

Effect ofMacitentan on the Development of New Ischemic Digital Ulcers in PatientsWith Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials

P. Merkel, D. Furst, C. Denton, 2016 .

Therapeutic trial of diazepam versus placebo in acute chloroquine intoxications of moderate gravity

E. Vicaut, G. Angel, F. Baud, 1996, Intensive Care Medicine.

Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

A. Torbicki, H. Ghofrani, G. Simonneau, 2015, JACC. Heart failure.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial

A. Torbicki, H. Ghofrani, G. Simonneau, 2018, PloS one.